Corvus Pharmaceuticals (NASDAQ:CRVS) Cut to “Strong Sell” at Wall Street Zen

Posted by George Bondi on Nov 10th, 2026

Wall Street Zen cut shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Free Report) from a sell rating to a strong sell rating in a research note published on Saturday,Wall Street Zen reports.

CRVS has been the subject of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a research note on Monday, October 26th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Corvus Pharmaceuticals in a report on Wednesday, September 16th. Mizuho set a $27.00 target price on shares of Corvus Pharmaceuticals in a research note on Thursday, October 29th. Finally, LADENBURG THALM/SH SH upgraded shares of Corvus Pharmaceuticals to a “strong-buy” rating in a report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Corvus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $32.83.

Read Our Latest Research Report on Corvus Pharmaceuticals

Corvus Pharmaceuticals Stock Up 7.7%

Shares of NASDAQ CRVS opened at $11.35 on Friday. Corvus Pharmaceuticals has a fifty-two week low of $6.39 and a fifty-two week high of $26.95. The company has a 50 day simple moving average of $11.44 and a two-hundred day simple moving average of $14.30.

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). Analysts predict that Corvus Pharmaceuticals will post -0.79 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Corvus Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CRVS. Global Retirement Partners LLC bought a new position in Corvus Pharmaceuticals in the 2nd quarter worth approximately $30,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Corvus Pharmaceuticals during the 2nd quarter valued at approximately $48,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Corvus Pharmaceuticals during the third quarter valued at approximately $50,000. State of Wyoming bought a new stake in shares of Corvus Pharmaceuticals during the second quarter valued at approximately $71,000. Finally, Meeder Asset Management Inc. bought a new stake in shares of Corvus Pharmaceuticals during the second quarter valued at approximately $90,000. Institutional investors own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

(Get Free Report)

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that harness the immune system to treat cancer. The company’s research centers on therapies designed to modulate immune-cell activity and address diseases with significant unmet medical needs.

Corvus’ leading product candidate is soquelitinib, formerly known as CPI-818, an oral, selective inhibitor of inducible T-cell kinase (ITK). The company is studying soquelitinib as a potential treatment for T-cell malignancies, including peripheral T-cell lymphoma.